Attached files

file filename
10-Q - FORM 10-Q - ACHILLION PHARMACEUTICALS INCd230843d10q.htm
EX-31.1 - SECTION 302 CEO CERTIFICATION - ACHILLION PHARMACEUTICALS INCd230843dex311.htm
EX-32.2 - SECTION 906 CFO CERTIFICATION - ACHILLION PHARMACEUTICALS INCd230843dex322.htm
EX-31.2 - SECTION 302 CFO CERTIFICATION - ACHILLION PHARMACEUTICALS INCd230843dex312.htm
EX-32.1 - SECTION 906 CEO CERTIFICATION - ACHILLION PHARMACEUTICALS INCd230843dex321.htm
EXCEL - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR3.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR7.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR5.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR6.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR1.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR9.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR8.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR2.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR16.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR12.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR15.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR14.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR11.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR10.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR13.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR17.htm
v2.3.0.15
Statements Of Operations (USD $)
In Thousands, except Per Share data
3 Months Ended9 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2011
Sep. 30, 2010
Statements Of Operations [Abstract]    
Revenue$ 64$ 170$ 185$ 431
Operating expenses    
Research and development8,6155,65725,50414,431
General and administrative1,9221,6906,5815,047
Total operating expenses10,5377,34732,08519,478
Loss from operations(10,473)(7,177)(31,900)(19,047)
Other income (expense)    
Interest income442711453
Interest expense(9)(67)(35)(243)
Net loss$ (10,438)$ (7,217)$ (31,821)$ (19,237)
Basic and diluted net loss per share (Note 5)$ (0.15)$ (0.15)$ (0.51)$ (0.47)
Weighted average shares used in computing basic and diluted net loss per share69,72547,57662,39240,608